Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus

Z.I. Cherney, David; A. Perkins, Bruce; Soleymanlou, Nima; Maione, M; Lai, Vesta; Lee, Alana; Fagan, Nora; J. Woerle, Hans; Erik Johansen, Odd; C. Broedl, Uli; von Eynatten, Maximilian

doi:10.1161/circulationaha.113.005081

Public

Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus

Published in Circulation • Dec 13, 2013

Authors:

David Z.I. Cherney

Bruce A. Perkins

Nima Soleymanlou

Abstract

BACKGROUND: The primary objective of this mechanistic open-label, stratified clinical trial was to determine the effect of 8 weeks' sodium glucose cotransporter 2 inhibition with empagliflozin 25 mg QD on renal hyperfiltration in subjects with type 1 diabetes mellitus (T1D). METHODS AND RESULTS: Inu...

Subject

Empagliflozin

Medicine

Renal function

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!